MEDACEF 125mg/5ml Price

Overview

Welcome to Dwaey, specifically on MEDACEF 125mg/5ml Suspension/Powder for page.
This medicine contains an important and useful components, as it consists of Cefaclor (as monohydrate).
MEDACEF 125mg/5ml is available in the market in concentration 125mg/5ml and in the form of Suspension/Powder for.

MEDPHARMA PHARMA. & CHEM. IND-S (L.L.C) is the producer of MEDACEF 125mg/5ml and it is imported from UAE, The most popular alternatives of MEDACEF 125mg/5ml are listed downward .

Mode Of Action

Cefaclor binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. It has bactericidal activity against gm-ve bacteria including E. coli, S. pneumoniae, N. gonorrhoea, P. mirabilis and H. influenzae.

Indication

• Pneumonia
• Meningitis
• Peritonitis
• Otitis media
• Septicaemia
• Biliary-tract infections
• Urinary-tract infections
• Skin and skin structure infections
• Upper and lower respiratory tract infections
• Pharyngitis and Tonsillitis

Precaution

Severe renal impairment; history of allergy to penicillin; pregnancy, lactation. Lactation: enters breast milk; use with caution

Side Effects

• 1-10% Diarrhea (3%)
• Increased transaminases (3%)
• Eosinophilia (2%)
• Moniliasis (2%)
• Vaginitis (2%)
• Rash (maculopapular
• erythematous
• or morbiliform) (1-2%) <1% Stevens-Johnson syndrome
• Pseudomembranous colitis
• Nausea
• Vomiting
• Anemia
• Neutropenia
• Jaundice Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis.

Contra indication

Known hypersensitivity to cephalosporins.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.